Supplementary Table 2.
Risk factors for 3-month mortality after EUS-hepaticogastrostomy for perihilar cholangiocarcinoma
| 3-month mortality after EUS-hepaticogastrostomy | ||||
|---|---|---|---|---|
|
| ||||
| Univariate analysis (OR [95% C.I.) | P | Multivariate analysis (OR [95% C.I.) | P | |
| Gender (male) | NS | NS | - | - |
| Age | NS | NS | - | - |
| Study period (2018-2020) | NS | NS | - | - |
| Bismuth-Corlette classification | NS | NS | - | - |
| Distant metastasis | NS | NS | - | - |
| Ascites | 12.4 [1.31-117.9] | 0.03 | NS | NS |
| Unfit for chemotherapy | 4.67 [1.00-22.8] | 0.05 | NS | NS |
| Basal bilirubin levels | NS | NS | - | - |
| Indication for biliary drainage | NS | NS | - | - |
| Clinical success | 0.10 [0.02-0.61] | 0.01 | NS | NS |
| Type of stent | NS | NS | - | - |
| Adverse event | NS | NS | - | - |
| Stent dysfunction | NS | NS | - | - |
| Need for reintervention | NS | NS | - | - |
| Chemotherapy start | 0.01 [0.00-0.15] | <0.001 | 0.01 [0.00-0.15] | <0.001 |
OR: Odd ratio, 95% C.I.: 95% confidence interval, NS: Not statistically significant